BridgeMD
Phase 3 Study to Evaluate Mezigdomide (CC-92480/BMS-986348) in Combination with Carfilzomib and Dexamethasone in Relapsed or Refractory Multiple Myeloma: SUCCESSOR-2
EU CTIS ID: 2022-500861-29-00
What this study is testing
To compare the progression-free survival (PFS) of CC-92480, carfilzomib and dexamethasone (480Kd) to that of carfilzomib and dexamethasone (Kd) in participants with relapsed or refractory multiple myeloma (RRMM)
- Therapeutic confirmatory (Phase III)
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- Participant has documented diagnosis of multiple myeloma (MM) and measurable disease, defined as any of the following: a. M-protein ≥ 0.5 g/dL by serum protein electrophoresis (sPEP) or b. M-protein ≥ 200 mg/24-hour urine collection by urine protein electrophoresis (uPEP) or, c. For participants without measurable disease in sPEP or uPEP: sFLC levels > 100 mg/L (10 mg/dL) involved light chain and an abnormal κ/λ FLC ratio.
- Participant has received at least 1 prior line of anti-myeloma therapy.
- Participant must have received prior treatment with lenalidomide and an anti-CD38 monoclonal antibody. For country-specific requirements, refer to Appendix12.
- Participant achieved minimal response (MR) or better to at least 1 prior anti-myeloma therapy.
- Participant must have documented disease progression during or after their last anti-myeloma regimen.
- Participant has an Eastern Cooperative Oncology Group (ECOG) performance status score of 0, 1, or 2.
You likely can't join if
- Participant who has had prior treatment with mezigdomide or carfilzomib.
- Participant who has had any investigational agents within 28 days or 5 half-lives (whichever is shorter) of initiating study intervention.
- Participant has previously received allogeneic stem cell transplantation at any time during prior therapy or received autologous stem cell transplantation within 12 weeks of initiating study intervention.
- Participant with known central nervous system (CNS) involvement with myeloma.
The study team makes the final eligibility decision.
Where it's taking place
- Hong Kong
- Australia
- United States
- United Kingdom
- Argentina
- Taiwan
- Colombia
- Japan
- India
- China
- Canada
- Brazil
- Singapore
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 65+ years, 18-64 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Hong Kong; Australia; United States; United Kingdom; Argentina; Taiwan and 7 more location(s). Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.